Home Stock

Stock Research: Roche

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Roche

VTX:ROG CH0012032048
59
  • Value
    49
  • Growth
    72
  • Safety
    Safety
    53
  • Combined
    61
  • Sentiment
    48
  • 360° View
    360° View
    59
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Roche Holding AG is a healthcare company focused on pharmaceuticals and diagnostics. The company operates in the pharmaceuticals and diagnostics industries with business segments in Pharmaceuticals (Roche Pharmaceuticals and Chugai) and Diagnostics (Diabetes Care, Molecular Diagnostics, Professional Diagnostics, and Tissue Diagnostics). The company develops medicines for oncology, immunology, infectious diseases, ophthalmology, and neuroscience. In the last fiscal year, the company had a market cap of $258,542 million, profits of $49,371 million, and revenue of $66,683 million, with 103249 employees.

more

ANALYSIS: With an Obermatt 360° View of 59 (better than 59% compared with alternatives), overall professional sentiment and financial characteristics for the stock Roche are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Roche. The consolidated Growth Rank has a good rank of 72, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 72% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 53 which means that the company has a financing structure that is safer than 53% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 49 which means that the share price of Roche is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 51% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 48, which means that professional investors are more pessimistic about the stock than for 52% of alternative investment opportunities. ...read more

more
Strongest Rank Analyst Opinions
Weakest Rank Profit Growth
Country Switzerland
Industry Pharmaceuticals
Size XX-Large
Website roche.com
Index
SPI
SPI
SMI
Roche stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
49 51 61 50
Growth
72 55 17 31
Safety
Safety
53 14 30 45
Sentiment
48 79 64 14
360° View
360° View
59 45 30 24
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
19 24 26 55
Opinions Change
55 75 54 16
Pro Holdings
n/a 92 63 30
Market Pulse
71 67 79 39
Sentiment
48 79 64 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
49 51 61 50
Growth
72 55 17 31
Safety Safety
53 14 30 45
Combined
61 22 14 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
47 31 39 36
Price vs. Earnings (P/E)
38 56 70 58
Price vs. Book (P/B)
19 10 12 10
Dividend Yield
78 87 90 86
Value
49 51 61 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
29 34 25 12
Profit Growth
100 51 29 37
Capital Growth
34 51 46 39
Stock Returns
74 80 36 76
Growth
72 55 17 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
22 12 20 43
Refinancing
53 22 21 14
Liquidity
68 63 73 74
Safety Safety
53 14 30 45

Similar Stocks

Discover high‑ranked alternatives to Roche and broaden your portfolio horizons.

Zehnder Group

SWX:ZEHN
Country: Switzerland
Industry: Building Products
Size: Medium
Full Stock Analysis

Bachem

SWX:BANB
Country: Switzerland
Industry: Life Sciences Tools & Services
Size: Medium
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews